2026-09-14 FDA Warning Letter: Celmade Cited for Review of Website/Unapproved New Drug/Misbranded
Letter issued · posted to fda.gov .
Subject as published: Review of Website/Unapproved New Drug/Misbranded
TL;DR
Key takeaway: On September 14, 2026, the FDA's Center for Drug Evaluation and Research (CDER) issued Warning Letter MARCS-CMS 735876 to Celmade (South Korea) for offering unapproved and misbranded injectable botulinum toxin products—including "Wonder tox 100" and "Wondertox 100 Unit"—for sale on websites www.celmade.co and www.celmade.net, in violation of sections 301(a), 301(d), 502(f)(1), 503(b)(1), and 505(a) of the Federal Food, Drug, and Cosmetic Act. The FDA stated these products lack required section 505 approved applications and pose serious safety risks, including infection, contamination, and variable ingredient content, and requested cessation of all unapproved and misbranded drug sales to U.S. consumers. The agency warned that failure to address violations may result in seizure, injunction, or other regulatory action.
Argus analysis
# FDA Warning Letter Analysis: Celmade
**Company and Violations**
Celmade, a South Korea–based entity, received a warning letter from the FDA's Center for Drug Evaluation and Research (CDER) on September 14, 2026, following website reviews conducted on August 4 and September 1, 2026. The FDA identified that Celmade's websites (www.celmade.co and www.celmade.net) were introducing unapproved and misbranded injectable botulinum toxin products into U.S. interstate commerce. The agency emphasized significant safety risks associated with unapproved botulinum toxin products, particularly the absence of medical supervision and the inherent dangers of injectable drugs that bypass natural body defenses.
**Regulatory Citations**
The violations cited sections 301(a), 301(d), 502(f)(1), 503(b)(1), and 505(a) of the Federal Food, Drug, and Cosmetic Act. Section 505(a) requires FDA approval before new drugs enter commerce; Celmade lacked approved applications for products like "Wonder tox 100" and "Wondertox 100 Unit." Section 502(f)(1) requires adequate directions for safe use by laypersons; prescription botulinum toxin products cannot meet this standard without licensed practitioner supervision. Section 503(b)(1) designates these products as prescription-only due to toxicity and method of administration. These violations typically indicate systemic regulatory non-compliance and potential public health risk.
**Response Timeline and Industry Outlook**
Celmade must submit a written response within 15 business days of receipt, detailing corrective actions and preventative measures. The response should address the root causes and include supporting documentation. Compliance officers in pharmaceutical and aesthetics sectors should monitor for FDA enforcement escalation—the agency indicated that seizures, injunctions, or detention of imported products remain possible if violations persist. Given the cross-border nature of this case, regulatory coordination with South Korean authorities is likely. Industry peers should note that FDA's Internet Pharmacy Task Force remains active in identifying and addressing unauthorized drug distribution channels.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Celmade MARCS-CMS 735876 — September 14, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Product: Drugs Recipient: Celmade South Korea Issuing Office: Center for Drug Evaluation and Research (CDER) United States September 14, 2026 www.celmade.co and www.celmade.net celmadesales@gmail.com, no-reply@celmade.co, wholesale@celmade.co WARNING LETTER Reference Number: MARCS-CMS 735876 To Celmade: This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your websites www.celmade.co and celmade.net. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that you comply with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. As discussed below, FDA has observed that www.celmade.co and celmade.net introduce into interstate commerce unapproved and misbranded injectable botulinum toxin drug products. FDA has identified significant risks associated with unapproved botulinum toxin products, especially in the absence of appropriate medical supervision. Furthermore, injectable drug products can pose a serious risk of harm to users because they bypass many of the body's natural defenses against toxic ingredients, toxins, or dangerous organisms that can lead to serious and life-threatening conditions such as septicemia or sepsis. There are also inherent risks to consumers who purchase unapproved new drugs and misbranded drugs. Unapproved new drugs do not carry the same assurances of safety and effectiveness as those drugs subject to FDA oversight. Drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether. Accordingly, FDA requests that www.celmade.co and celmade.net cease offering any unapproved and misbranded drugs for sale to U.S. consumers. This is critical to shielding the American public from harm. FDA Review Violations were identified and documented during a review of your websites www.celmade.co on August 4, 2026, and celmade.net on September 1, 2026 (FDA Establishment Identifier (FEI) 3038674250). Violations of the Federal Food, Drug, and Cosmetic Act On your websites at internet address www.celmade.co and celmade.net, you introduce into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), 301(d), 502(f)(1), 503(b)(1), and 505(a) of the Federal Food, Drug, and Cosmet…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- When did FDA issue the warning letter to Celmade?
- FDA issued the letter (MARCS-CMS 735876) on 2026-09-14 and posted it publicly on fda.gov on 2026-09-29.
- Is the FDA warning letter to Celmade publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/celmade-735876-09142026.
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
- What is the regulatory background for a Unapproved drug warning letter?
- Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). 2026-09-14 FDA Warning Letter: Celmade Cited for Review of Website/Unapproved New Drug/Misbranded. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-celmade-2026-09-14-unapproved-drug
"2026-09-14 FDA Warning Letter: Celmade Cited for Review of Website/Unapproved New Drug/Misbranded." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-celmade-2026-09-14-unapproved-drug.
Argus HQ Research. "2026-09-14 FDA Warning Letter: Celmade Cited for Review of Website/Unapproved New Drug/Misbranded." Digital Empire Holdings LLC. Accessed September 30, 2026. https://argushq.ai/fda/warning-letter/fda-wl-celmade-2026-09-14-unapproved-drug.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_celmade_2026_09_14_unapproved_drug_2026,
title = {2026-09-14 FDA Warning Letter: Celmade Cited for Review of Website/Unapproved New Drug/Misbranded},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-celmade-2026-09-14-unapproved-drug},
note = {Accessed: September 30, 2026}
}